Exelixis | EXEL - Zapasy





Zapasy Zmiana Data
Acadia Pharmaceuticals USD 34.67M 5.57M 2025-12
Agios Pharmaceuticals USD 35.09M 2.17M 2026-03
Akebia Therapeutics USD 15.61M 3.03M 2025-12
Amgen USD 6.22B 121M 2025-12
AstraZeneca USD 6.57B 13M 2026-03
Bayer EUR 12.33B 221M 2025-09
BioMarin Pharmaceutical USD 1.3B 83.29M 2025-12
Bristol-Myers Squibb USD 2.76B 66M 2026-03
Cytokinetics USD 0 0 2023-12
Eisai JPY 236.46B 9.14B 2025-09
Eli Lilly USD 14.53B 785M 2026-03
Esperion Therapeutics USD 108.54M 5.93M 2025-09
Exelixis USD 27.4M 3.92M 2025-09
Genmab DKK 13M 1000K 2025-06
Glaxosmithkline GBP 6.12B 46M 2025-09
Incyte USD 115.62M 14.56M 2026-03
Ionis Pharmaceuticals USD 5.56M 4.49M 2026-03
MacroGenics USD 7.91M 840K 2025-12
Merck USD 6.66B 214M 2025-12
Moderna USD 332M 92M 2025-09
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 69M 300K 2025-12
Novartis USD 6.27B 152M 2025-12
Pfizer USD 11.47B 201M 2025-09
Puma Biotechnology USD 9.48M 885K 2025-09
Sanofi EUR 22.69B 1.81B 2025-12
Takeda JPY 1.41T 107.71B 2025-12
Ultragenyx Pharmaceutical USD 52.2M 5.7M 2025-09